Thyroid Gland Disorders Treatment Market Report

The global thyroid gland disorders treatment market size was accounted for over USD 2 billion in 2019 and projected to grow at the CAGR of 3.6% market during the forecast period 2020-2027. Thyroid gland disorder is characterized by underactive or overactive production of thyroid hormones (T3 and T4), termed as hypothyroidism or hyperthyroidism respectively. Thyroid disorders can range from a small, harmless goiter (enlarged gland) that needs no treatment to life-threatening cancer. The most common thyroid problems involve abnormal production of thyroid hormones. Thyroid gland disorders affect around 5% to 10% of the human population globally. Women are more susceptible to thyroid problems.

Market Insights:

Rising numbers of thyroid gland disorder patients is the key driver for global thyroid gland disorder treatment market. The thyroid gland disorders treatment market is increasing due to the factors such as rise in the patient numbers suffering from thyroid disorders, aging population and early disease diagnosis and treatment. Moreover, growing demand for hypothyroidism drugs such as Synthroid and Euthyrox in the developing as well as developed region would further drive the market growth. The global thyroid gland disorder treatment market is currently dominated by North America due to increasing number of thyroid gland disorder patients, rising public awareness and early disease diagnosis and supportive reimbursement scenario. Asia Pacific is anticipated to be the fastest growing market for thyroid gland disorder treatment, the driving factors are lucrative opportunities to manufacturers of thyroid gland disorder treatment drugs, increasing number of thyroid gland disorder patients and developed healthcare infrastructure.

Market Segment Insights:

The thyroid gland disorders treatment market is majorly segmented into hypothyroidism (Levothyroxine, Liothyronine) and hyperthyroidism treatment (Imidazole, Propacil). The market growth is attributed mainly due to factors such as rise in the patient base suffering from thyroid disorders, rising geriatric population and consistent introduction of new drug therapeutics by pharmaceutical companies lead. Moreover, growing demand for hypothyroidism drugs such as Synthroid and Euthyrox in the developing as well as developed region would further drive the market growth.

Global Thyroid gland Disorder Treatment Market Segmentation:

By Treatment, 2018–2027 ($ Millon)

• Hypothyroidism
  • Levothyroxine
  • Liothyronine
• Hyperthyroidism
  • Imidazole
  • Propacil

By Geography, 2018-2027 ($ Millon)

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regional Insights:

North America, Latin America, Europe, Middle East and Africa and Asia Pacific, markets together form the major regional markets for thyroid gland disorder treatment market. These regional markets are further sub-segmented into country specific markets on the basis of demand and market growth of thyroid gland disorder treatment market. Among the considered regional markets, North America currently dominates the global thyroid gland disorders treatment market, with United Sates being the largest county-level market. Increase in number of patients suffering from thyroid disease, rising public awareness and supportive reimbursement policies. Furthermore, Asia Pacific is anticipated to be the fastest growing market for thyroid gland disorders treatment market, the driving factors are lucrative opportunities to manufacturers of thyroid gland disorder treatment drugs, large patient pool and developed healthcare infrastructure.

Market Competition Assessment:

Key players in the global thyroid gland disorder treatment market are AbbVie, Inc., Mylan N.V., Abbott Laboratories, Merck KGaA, Pfizer, Inc., Sanofi, GlaxoSmithKline plc, Novartis AG and others.

List of Key Companies:

• Abbott Laboratories
• Abbvie, Inc.
• Allergan plc
• GlaxoSmithKline plc
• Lannett Company Inc.
• Merck KGaA
• Mylan N.V.
• Novartis AG
• Sanofi
• Takeda Pharmaceutical Company Ltd

Key Questions Answered by Thyroid Gland Disorders Treatment Market Report

• Global thyroid gland disorders treatment market forecasts from 2020-2027
• Regional thyroid gland disorders treatment market forecasts from 2020-2027 covering Asia-Pacific, North America, Europe, Middle East and Africa, and Latin America
• Country level forecasts from 2020-2027 covering 15 major countries from aforementioned regions
• Thyroid Gland Disorders Treatment submarket forecasts from 2020-2027 covering the market by treatment, and geography
• Various industry models such as SWOT analysis, Pestle Analysis, Porter’s Five Force model, Value Chain Analysis pertaining to thyroid gland disorders treatment market
• Analysis of the key factors driving and restraining the growth of the global, regional and country level thyroid gland disorders treatment markets from 2020-2027
• Competitive Landscape and market positioning of top 10 players operating in the thyroid gland disorders treatment market

Request a full report sample @ https://www.researchcorridor.com/request-sample/?id=27514

Table of Content:

Chapter 1 Preface

1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology

Chapter 2 Executive Summary

2.1 Global Thyroid Gland Disorders Treatment Market Portraiture
2.2 Global Thyroid Gland Disorders Treatment Market, by Treatment, 2019 ($ Million)
2.3 Thyroid Gland Disorders Treatment Market Share, by Geography, 2019 (Value %)

Chapter 3 Thyroid Gland Disorders Treatment: Market Dynamics and Outlook

3.1 Introduction, Facts and Figures
3.2 Epidemiology of Thyroid Disorders
3.3 Market Dynamics
3.3.1 Drivers
3.3.1.1 Rising Geriatric Population
3.3.1.2 Government Initiative
3.3.2 Challenges
3.3.2.1 Rising Consumption of Generic Drugs
3.3.3 Opportunities
3.3.3.1 Technological Advancements
3.4 Regulatory Framework
3.5 Attractive Investment Proposition
3.6 Competitive Analysis
3.6.1 Market Share Analysis by Key Players, 2016 (Value %)

Chapter 4 Thyroid Gland Disorders Treatment Market, by Treatment Type, 2018-2027 ($ Million)

4.1 Preface
4.2 Hypothyroidism
4.2.1 Levothyroxine
4.2.2 Liothyronine
4.3 Hyperthyroidism
4.3.1 Imidazole
4.3.2 Propacil

Chapter 5 Thyroid Gland Disorders Treatment Market, by Geography 2018-2027 ($ Million)

5.1 Overview
5.2 North America
5.2.1. U.S.
5.2.2. Canada
5.3 Europe
5.3.1. U.K.
5.3.2. Germany
5.3.3. Rest of Europe
5.4 Asia Pacific
5.4.1. Japan
5.4.2. China
5.4.3. Rest of Asia Pacific
5.4 Latin America
5.4.1. Brazil
5.4.2. Mexico
5.4.3. Rest of Latin America
5.5 Middle East and Africa
5.5.1. GCC
5.5.2. Rest of Middle East and Africa

Chapter 6 Company Profiles

6.1 Abbott Laboratories
6.2 Abbvie, Inc.
6.3 Allergan plc.
6.4 GlaxoSmithKline plc
6.5 Merck KGaA
6.6 Mylan N.V.
6.7 Novartis AG
6.8 Lannett Company Inc.
6.9 Sanofi
6.10 Takeda Pharmaceutical Company Ltd
6.11 Other Notable Players